Navigation Links
Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD
Date:1/31/2008

CINCINNATI, Jan. 31 /PRNewswire/ -- Medpace, a leading global full-service contract research organization, announced it has hired Jim Wei, MD, PhD, as Director of Clinical Pharmacology.

Dr. Wei joins Medpace with extensive experience in the clinical trial regulatory aspects of early phase cardio-metabolic studies. He will consult with sponsors on their clinical trial programs and provide recommendations as to which studies merit inclusion in the programs and how the studies should be designed and analyzed.

Dr. Wei comes to Medpace from the FDA where he served as a Senior Reviewer in the Office of Clinical Pharmacology for almost 10 years. He was heavily involved in reviewing NDAs and INDs for the Division of Metabolism and Endocrinology Products. He was an active member of both the Drug Metabolism/Drug Interaction and Pharmacogenetics/Pharmacogenomics Working Groups. Previous to his work at the FDA, he was an Intramural Research Training Award (IRTA) Fellow at the Laboratory of Metabolism at the National Cancer Institute, a Fellow in the Clinical Pharmacology Section at the Veteran Affairs Medical Center in Boise, Idaho, and a staff physician in the Division of Cardiology and Clinical Pharmacology at the Zhejiang Medical University Hospital in China.

Dr. Wei received his medical degree from the Zhejiang Medical University and his PhD from the College of Pharmacy at Idaho State University. He is certified by the American Board of Clinical Pharmacology and is a member of the American Society of Clinical Pharmacology and Therapeutics. He was a previous member of the International Society of Study of Xenobiotics. Dr. Wei has presented many topics on drug metabolism/drug interaction, pharmacogenetics, and risk assessment in drug development at regional, national, and international conferences. He has published more than 20 peer reviewed articles and book chapters.

"We are excited to have an experienced clinical pharmacologist with extensive FDA experience such as Jim Wei," said August Troendle, MD, Medpace Chief Executive Officer. "Jim's clinical pharmacology expertise, particularly for the cardio-metabolic field, is a good fit for our company based on our therapeutic focus. He will be invaluable to our clients who need assistance with strategy and execution for their clinical development programs."

About Medpace

Medpace is a global, research-based drug development company led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 500 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

The Medpace group of companies also includes:

Imagepace - a core imaging laboratory

Medpace Reference Laboratories - a centralized lab with therapeutically

specialized testing

Medpace Clinical Pharmacology - a Phase I/IIa unit

View the Medpace website at http://www.medpace.com.

Contact: John Wynne, 513-579-9911 x2407

j.wynne@medpace.com


'/>"/>
SOURCE Medpace, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medpace Strengthens Presence in Central Europe
2. Third Security, LLC Hires Two New Managing Directors
3. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
4. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
5. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
6. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
7. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
8. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
9. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
10. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
11. MedImmune Announces Seven Key Promotions and New Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ... 21 st .  The commercials will air on Bloomberg TV, ... the Street show. --> NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ...
Breaking Biology News(10 mins):